VISCHER advises the new investors in the Series B financing. of Xeltis AG, Zurich, a privately-held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery raising EURO 27 million (USD 34 million/CHF 32 million). The financing was lead by Life Sciences Partners, Amsterdam (LSP) and Kurma Partners, Paris , with participation from VI Partners, Zug (VI) and current shareholders of Xeltis. The financing will primarily be used to fund market access activities for the company’s first product, a pulmonary valve, and the development of the company’s product pipeline. The VISCHER Team was led by Dr. Matthias Staehelin (Partner) with Marius Meier (Managing Associate) and Dania Salvisberg-Schneider (Associate),all Corporate.